African Medicines Agency Moves From Treaty to Regulatory Architecture
The African Medicines Agency is no longer just an idea on paper. It now sits at the center of a continent-wide effort to reduce the regulatory fragmentation that has long slowed access to safe, effective, and quality-assured medical products across Africa.
A narrative review published in Frontiers in Medicine traces how that effort evolved from the African Medicines Regulatory Harmonisation Programme, launched by the African Union in 2009, into a treaty-based agency with a defined governance structure and early operational pilots. The account places the AMA within a broader public health problem: when countries rely on divergent regulatory pathways, medicine approval becomes slower, duplication increases, and the same product can face uneven standards from one jurisdiction to the next.
The policy logic is straightforward. Harmonized regulation does not merely simplify paperwork; it can shape whether patients receive quality-assured medicines in time, whether manufacturers face predictable requirements, and whether regulators can use limited technical capacity more efficiently.
From AMRH to Treaty Adoption
The review describes the AMRH Programme as the foundation for continental regulatory convergence. That initiative created the institutional momentum needed for the AMA, which was formally established by treaty adopted by African Union heads of state and government in 2019 and entered into force in November 2021.
By June 2025, 31 AU member states had ratified the treaty. In governance terms, the agency is designed around a Conference of State Parties, a Governing Board, a Secretariat, and Technical Committees. Each element serves a distinct regulatory function, from political oversight to technical evaluation and administrative coordination.
One sentence captures the practical weight of that shift: fragmented medicine regulation is being replaced by a continent-level legal framework.
For regulators, that matters because legal authority is the skeleton on which every other function depends. Without a treaty, harmonization can remain voluntary and uneven. With a treaty, states have a shared institutional anchor for convergence, reliance, and coordinated review. The review places that legal evolution at the center of the AMA’s identity rather than treating it as a symbolic milestone.
Why Continental Regulation Matters for Access and Quality
Across many African health systems, regulatory capacity is uneven. Some national agencies have deeper technical expertise, larger staffs, and more mature review processes, while others operate with far fewer resources. The result is a patchwork system in which a medicine may move quickly in one country but face delays in another, even when the underlying evidence package is the same.
The review links this fragmentation to delayed access to medical products that are safe, effective, and quality-assured. It also frames the AMA as a response to a structural problem in public health delivery, not just a bureaucratic reform. Regulatory delay can ripple into treatment access, procurement planning, and market predictability. When countries duplicate the same evaluations independently, scarce expertise is spread thin and timelines stretch.
The agency’s promise rests on one central pharmacoregulatory principle: if authorities can trust each other’s assessments under a common framework, review cycles can shorten without sacrificing standards. That is the rationale behind reliance mechanisms, which allow regulators to use work already completed by trusted counterparts rather than repeating every step from scratch.
Continental Listing Tests Reliance in Real Time
The review pays particular attention to operational pilots, especially the Continental Listing of Human Medicinal Products introduced through AMRH since 2023. These pilots are not decorative projects; they are the first tests of whether harmonized systems can function beyond treaty language.
The Continental Listing demonstrated the feasibility of reliance mechanisms. In regulatory science, that is an important proof-of-concept because it shows that continental coordination can move from policy aspiration to practical workflow. A listing system can help create a shared reference point for product evaluation, reducing duplication and giving member states a more common evidentiary base.
The pilot also exposes the friction points that still sit beneath the surface. National legal systems do not harmonize themselves simply because a continental agency exists. Domestic statutes, procedural rules, and enforcement mechanisms still vary widely. Funding remains uneven, and so does technical capacity. Those constraints can slow implementation even when the institutional design is strong.
Governance Strength Without Operational Equality
The review presents the AMA as an institution with serious structural ambition, but structure alone does not produce uniform performance. The Governing Board, Secretariat, and Technical Committees can coordinate decision-making, yet national implementation still depends on whether member states have the legal tools and financial capacity to act on continental decisions.
This tension is familiar in health regulation. High-level agreements often move faster than the systems needed to support them. A treaty can define authority, but staffing, information systems, legal alignment, and budget commitments determine whether that authority becomes daily practice. The AMA sits exactly at that intersection.
The review therefore treats operationalization as the next critical phase. The treaty provides legitimacy. The pilots provide early evidence that reliance can work. What remains is the harder task of converting continental design into consistent national execution.
Public Health Consequences of Delayed Harmonization
The public health implications are immediate. Slow or inconsistent medicine regulation can delay patient access, prolong shortages, and create uncertainty for manufacturers and procurement bodies. In settings already strained by infectious disease burden, noncommunicable disease growth, and limited health financing, regulatory delay is not an abstract administrative issue.
It is a bedside issue.
When quality-assured products reach markets later than they should, clinicians and patients feel the consequences directly. When regulatory standards differ too widely, confidence in product quality weakens. The AMA’s central value lies in reducing those gaps while preserving technical rigor.
The review also situates the agency within a broader continental effort to strengthen public health systems. Harmonized regulation can support not only medicine access but also trust in the integrity of supply chains, review processes, and cross-border coordination.
Ratification, Capacity, and the Road Ahead
As of June 2025, 31 member states had ratified the treaty, but broad adoption alone will not guarantee uniform progress. The review identifies national legal harmonization, funding, and capacity disparities as the principal barriers to full implementation. Those barriers will shape how quickly the AMA can function as an operational regulatory authority rather than a formal institution with partial reach.
The review closes with a measured assessment: the AMA is a major step toward regulatory convergence in Africa, and its treaty framework, together with pilot outcomes, gives the continent a credible base for long-term operational success. The unresolved questions are concrete ones — how fast member states align domestic law, how reliably the agency is funded, and whether technical capacity can be scaled across settings with very different regulatory starting points.
The agency’s future will depend less on the symbolism of its creation than on whether it can make medicine regulation faster, more coherent, and more dependable across the continent.